The Drug Science Podcast T21 - Medical Cannabis bonus episode
T21 (formerly Project Twenty21) is a pioneering medical cannabis registry launched in the United Kingdom in 2019. It aims to create the UK's largest body of evidence for the effectiveness and tolerability of medical cannabis in treating a range of conditions.
T21 focuses on patients with conditions that can be treated with medical cannabis such as chronic pain, anxiety conditions, epilepsy, multiple sclerosis, post-traumatic stress disorder (PTSD), Tourette's syndrome, and substance use disorder. A list of conditions that qualify for medical cannabis treatment can be found here. The registry provides patients with access to discounted medical cannabis from licensed producers and clinicians who have undergone training in the use of medical cannabis while collecting data to strengthen the evidence base The project is seen as a significant step forward in promoting research into the potential therapeutic benefits of medical cannabis, and in improving patient access to this treatment option in the UK.
In this very special episode of the Drug Science Podcast, we will be joined by three members of the Drug Science team:
David Badcock – Chief Executive Officer of Drug Science
Prof Michael Lynskey – Chief Research Officer
Alkyoni Athanasiou-Fragkouli – Research Officer for T21
*Please note that in this episode we make reference to a medical cannabis legal document that will be provided in the shownotes, this document is VERY close to being finished but it needs a few last-minute reviews to ensure that all of the information is 100% accurate, we appreciate your patience.
David Nutt >< David Badcock Hepatitis C project
T21 latest data & data nuggets
T21 publications:
· The value of real world evidence: The case of medical cannabis